0001428336-23-000007.txt : 20230214 0001428336-23-000007.hdr.sgml : 20230214 20230214160330 ACCESSION NUMBER: 0001428336-23-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230214 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 23628624 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20230214.htm 8-K hqy-20230214
0001428336false00014283362023-02-142023-02-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 14, 2023
HEALTHEQUITY, INC.

Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02    Results of Operations and Financial Condition
On February 14, 2023, HealthEquity, Inc. (the “Company”) issued the press release attached as Exhibit 99.1 to this current report on Form 8-K.
The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description
99.1
104
Cover Page Interactive Data File (formatted in Inline XBRL)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: February 14, 2023By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:Executive Vice President and Chief Financial Officer



EX-99.1 2 pressrelease-fy23salesmetr.htm EX-99.1 Document

HealthEquity Reports Record HSA Sales, Asset Growth
Updates Previous Fiscal 2023 Guidance, Announces Investor Conferences, Presentations
Draper, Utah – February 14, 2023 – HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced HSA Assets and Total Accounts as of its fiscal year ended January 31, 2023. The Company also updated its previously announced FY23 guidance and announced upcoming investor conferences and presentations.
The total number of HSAs as of January 31, 2023, was 8.0 million, an increase of 11%, from 7.2 million as of January 31, 2022. The Company closed its fiscal year 2023 with 14.9 million Total Accounts, an increase of 4%, from 14.4 million as of January 31, 2022. HSA Assets grew to $22.1 billion as of January 31, 2023, an increase of 13% from $19.6 billion a year earlier.
“Team Purple finished fiscal 2023 with record sales of nearly 1 million new HSAs and with $22 billion of HSA assets,” said President and CEO Jon Kessler. “We are grateful to our many partners and clients working together with us to help an increasing number of American families connect health and wealth and enabling millions to achieve wellness today and financial well-being tomorrow.”
Also commenting, Tyson Murdock, Executive Vice President and CFO of HealthEquity, said, “With the record-setting sales year we are reporting today, we expect to reach the top-end of previously provided ranges for revenue and earnings, including revenue of approximately $860 million for our fiscal year ended January 31, 2023. We provided initial guidance for fiscal 2024 on December 6, 2022, and expect to update that guidance in our Q4 earnings release scheduled for March 21, 2023.”
Total Accounts (unaudited)
(in thousands, except percentages)January 31, 2023January 31, 2022% Change
HSAs7,984 7,207 11 %
New HSAs from sales - Quarter-to-date445 472 (6)%
New HSAs from sales - Year-to-date971 918 %
New HSAs from acquisitions - Year-to-date90 740 (88)%
HSAs with investments541 455 19 %
CDBs6,933 7,192 (4)%
Total Accounts14,917 14,399 %
Average Total Accounts - Quarter-to-date14,677 14,326 %
Average Total Accounts - Year-to-date14,531 13,450 %
HSA Assets (unaudited)
(in millions, except percentages)January 31, 2023January 31, 2022% Change
HSA cash$14,199 $12,943 10 %
HSA investments7,947 6,675 19 %
Total HSA Assets22,146 19,618 13 %
Average daily HSA cash with yield - Year-to-date13,049 10,579 23 %
Average daily HSA cash with yield - Quarter-to-date13,375 12,118 10 %
In previous years, the Company provided its initial business outlook for the following fiscal year in connection with reporting its sales results in February. With the Company providing its initial business outlook for fiscal year 2024 in its third quarter earnings report in December and fiscal 2023 sales results in line with previously provided estimates, the Company will not be hosting an investor call today, but its management team plans to present and meet with investors at the following upcoming investor conferences:
BTIG Virtual Medtech, Digital Health, Life Science and Diagnostic Tools Conference
Date:        February 15, 2023
Location:    Snowbird Ski Resort
Time:        Scheduled one-on-one meetings
Webcast:    None



Baird’s Silicon Slopes Event
Date:        March 2, 2023
Location:    Waldorf Astoria Park City
Time:        3:50 pm Mountain Time
Webcast:    None
Raymond James 44th Annual Institutional Investors Conference
Date:        March 6, 2023
Location:    JW Marriott Grande Lakes Orlando
Time:        1:05 pm Eastern Time
Webcast:    None
Non-GAAP financial information
Our previously provided guidance for fiscal year 2023 includes certain non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share, to supplement our financial information presented on a GAAP basis. For definitions of these non-GAAP measures, as well as reconciliations of the applicable non-GAAP financial measures to the most closely applicable GAAP financial measures, see our press release issued on December 6, 2022. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our more than 14 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
the impact of societal and economic changes arising out of the COVID-19 pandemic on the Company, its operations and its financial results;
our ability to realize the anticipated financial and other benefits from combining the operations of recent and future acquisitions with our business successfully;
our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;



the significant competition we face and may face in the future, including from those with greater resources than us;
our reliance on the availability and performance of our technology and communications systems;
potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
our reliance on partners and third-party vendors for distribution and important services;
our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
our ability to protect our brand and other intellectual property rights; and
our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2022, our Quarterly Report on Form 10-Q for the quarter ended April 30, 2022, and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact
Richard Putnam
801-727-1209
rputnam@healthequity.com



Certain terms
TermDefinition
HSAA financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDBConsumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA memberConsumers with HSAs that we serve.
Total HSA Assets
HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner.
Total AccountsThe sum of HSAs and CDBs on our platforms.



EX-101.SCH 3 hqy-20230214.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hqy-20230214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover page. Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 hqy-20230214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page
Feb. 14, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 14, 2023
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
XML 7 hqy-20230214_htm.xml IDEA: XBRL DOCUMENT 0001428336 2023-02-14 2023-02-14 0001428336 false 8-K 2023-02-14 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20230214.htm hqy-20230214.xsd hqy-20230214_lab.xml hqy-20230214_pre.xml pressrelease-fy23salesmetr.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20230214.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "hqy-20230214.htm" ] }, "labelLink": { "local": [ "hqy-20230214_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20230214_pre.xml" ] }, "schema": { "local": [ "hqy-20230214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20230214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230214.htm", "contextRef": "i588fd737bd764743a186a6b648f31563_D20230214-20230214", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230214.htm", "contextRef": "i588fd737bd764743a186a6b648f31563_D20230214-20230214", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001428336-23-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-23-000007-xbrl.zip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